15 / 18
Primary endpoint: PFS (investigator-assessed)
CI, confidence interval; NR, not reached.
Goserelin included in all combinations.
Probability of PFS (%)
Time (months)
No. at risk
Ribociclib + tamoxifen/NSAI
335 301 284 264 245 235 219 178 136 90 54 40
20
3
1
0
Placebo + tamoxifen/NSAI
337 273 248 230 207 183 165 124 94 62 31 24
13
3
1
0
PFS (investigator
assessment)
Ribociclib + tamoxifen/NSAI n=335 Placebo + tamoxifen/NSAI
n=337
Number of events, n (%)
131 (39.1)
187 (55.5)
Median PFS, months
(95% CI)
23.8
(19.2–NR)
13.0
(11.0–16.4)
Hazard ratio (95% CI)
0.553 (0.441–0.694)
One-sided p value
0.0000000983
10
8
6
4
2
0
100
80
60
40
20
0
30
28
26
24
22
20
18
16
14
12
10
30
50
70
90